CKD-506

CKD-506 is a novel, orally administered small molecule that acts as a highly selective inhibitor of histone deacetylase 6 (HDAC6). Developed by Chong Kun Dang Pharmaceutical, it is being investigated primarily for the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF). The drug exerts its effects by inhibiting HDAC6 activity, leading to increased acetylation of α-tubulin and modulation of immune cell function. This results in suppression of pro-inflammatory cytokines like TNF-α, IL-6, and IL-8 through inhibition of the NF-κB signaling pathway in immune cells. Preclinical studies have demonstrated efficacy in models of colitis, arthritis, multiple sclerosis (EAE model), and pulmonary fibrosis. Clinical trials have shown that CKD-506 is safe and well-tolerated in healthy volunteers[1][2][3][5][6][7][8].